Patents by Inventor James Maxwell Rennie

James Maxwell Rennie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INJECTABLE FORMULATIONS
    Publication number: 20220313660
    Abstract: Provided herein are pharmaceutical formulations, methods for their production, and uses thereof. The pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound, a buffer, which is separate to the salt, and water. The formulations have pH values of from about 3.5 to about 6.5 and osmolalities of about 250 to about 350 mOsm/Kg. Such formulations are suitable for injection, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.
    Type: Application
    Filed: June 13, 2022
    Publication date: October 6, 2022
    Applicant: Small Pharma Ltd
    Inventors: Marie Claire LAYZELL, James Maxwell RENNIE
  • Injectable formulations
    Patent number: 11406619
    Abstract: Provided herein are pharmaceutical formulations, methods for their production, and uses thereof. The pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound, a buffer, which is separate to the salt, and water. The formulations have pH values of from about 3.5 to about 6.5 and osmolalities of about 250 to about 350 mOsm/Kg. Such formulations are suitable for injection, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: August 9, 2022
    Assignee: SMALL PHARMA LTD
    Inventors: Marie Claire Layzell, James Maxwell Rennie
  • INJECTABLE FORMULATIONS
    Publication number: 20220062238
    Abstract: Provided herein are pharmaceutical formulations, methods for their production, and uses thereof. The pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound, a buffer, which is separate to the salt, and water. The formulations have pH values of from about 3.5 to about 6.5 and osmolalities of about 250 to about 350 mOsm/Kg. Such formulations are suitable for injection, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.
    Type: Application
    Filed: August 27, 2021
    Publication date: March 3, 2022
    Applicant: SMALL PHARMA Ltd
    Inventors: Marie Claire Layzell, James Maxwell Rennie
  • INJECTABLE FORMULATION
    Publication number: 20220062237
    Abstract: Described herein are pharmaceutical formulations, methods for their production, and uses thereof. The pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound, a buffer, which is separate to the salt, and water. The formulations have pH values of from about 3.5 to about 6.5 and osmolalities of about 250 to about 350 mOsm/Kg. Such formulations are suitable for injection, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.
    Type: Application
    Filed: August 28, 2020
    Publication date: March 3, 2022
    Applicant: SMALL PHARMA LTD
    Inventors: Marie Claire Layzell, James Maxwell Rennie